Summary
-If this trial shows significant clinical benefit, it will bring this drug one step forward towards approval in the US. This drug has already shown benefit for pancreatic and colorectal tumors, with minimal side effects. There is strong scientific and preclinical testing testifying to the in vitro efficacy of this antineoplastic agent. -Further future studies should be aimed at Glioblastoma Multiforme patients, as these tumors are the most common primary malignant tumors, and larger studies can be designed with high statistical significance.
Analysis
-If Nimotuzumab is eventually approved, it would represent major competition for Temodar, the current standard in chemotherapy from Schering Plough (SGP:NYSE). Much research will have to be done still to compare the efficacy of these two agents for glioma.
